Daily Respiratory Research Analysis
Analyzed 166 papers and selected 3 impactful papers.
Summary
Three impactful respiratory studies span diagnostics, environmental risk, and neonatal care. An integrated host–microbiome metatranscriptomic analysis in ventilated children distinguishes true lower respiratory infection from incidental pathogen carriage and yields a clinically promising biomarker (FABP4). A multicentre cohort links short- and long-term ambient air pollution—especially carbon monoxide—to ARDS and 30‑day mortality in COVID‑19. A randomized trial finds LISA and ENSURE surfactant delivery strategies comparable in preterm infants.
Research Themes
- Host–microbiome diagnostics for lower respiratory infections
- Ambient air pollution and acute respiratory outcomes
- Neonatal surfactant delivery strategies in preterm respiratory distress
Selected Articles
1. Host-microbiome archetypes differentiate infection from pathogen carriage in the human lower airway.
In mechanically ventilated children, integrated host–microbiome metatranscriptomics distinguished true lower respiratory infection from incidental carriage and non-infectious respiratory failure. A combined classifier achieved AUC 0.89, and single-gene FABP4 (protein) alone reached AUC 0.88, highlighting a practical biomarker for LRTI triage.
Impact: This study provides a clinically actionable, biology-informed framework to separate infection from colonization, a core challenge in ICU antibiotic stewardship. Identification of FABP4 as a standalone biomarker enables near-term translation.
Clinical Implications: Implementing host–microbe-informed diagnostics (e.g., FABP4 testing) could improve antibiotic decision-making in ventilated children by distinguishing LRTI from carriage and reducing overtreatment.
Key Findings
- Airway microbiome in LRTI showed reduced alpha diversity and richness; IPC had higher bacterial load, anaerobe enrichment, and increased metabolic activity.
- Host transcriptomes in LRTI revealed innate and adaptive immune activation; IPC resembled non-infectious controls.
- An integrated host–microbe classifier discriminated LRTI from IPC/controls (AUC 0.89); FABP4 protein alone achieved AUC 0.88.
Methodological Strengths
- Host–microbiome metatranscriptomic profiling with clinically adjudicated phenotypes
- Integrated machine-learning classifier with performance metrics and mediation analyses
Limitations
- Conducted in mechanically ventilated pediatric ICU patients, which may limit generalizability to non-intubated populations
- Cross-sectional sampling without external validation cohorts
Future Directions: Prospective external validation across age groups and care settings; development of rapid assays for FABP4; integration into antimicrobial stewardship workflows with outcome assessment.
Distinguishing lower respiratory tract infection (LRTI) from incidental pathogen carriage (IPC) is clinically challenging. The immunologic and microbial factors defining the states of LRTI and IPC are poorly understood. Here, we perform host-microbe metatranscriptomic profiling of tracheal aspirates from 326 mechanically ventilated children with clinically adjudicated LRTI (n = 207), IPC (n = 70), or non-infectious respiratory failure (n = 49). In the airway microbiome, LRTI shows reduced alpha diversity and taxonomic richness, while IPC displays greater bacterial abundance, enrichment in respiratory anaerobes, and increased metabolic activity. At the host level, patients with LRTI exhibit a distinct lower airway transcriptional signature of innate and adaptive immune activation compared to those with IPC, who have similar transcriptional profiles to uninfected controls. Mediation analyses suggest the airway microbiome influences the host response to pathogens. An integrated host-microbe metatranscriptomic classifier accurately discriminates LRTI from IPC and controls (AUC = 0.89, 95% confidence interval (CI) 0.85-0.92). The single gene FABP4, encoding a macrophage-associated lipid chaperone and recently described pneumonia biomarker, performs similarly when combined with alpha diversity; FABP4 protein alone achieves an AUC = 0.88 (95% CI 0.82-0.93). Together, our findings reveal distinct ecological and immunologic archetypes defining LRTI and IPC, and support data-driven, biology-informed LRTI diagnostics incorporating host and microbial features.
2. Ambient Air Pollution and Risk of ARDS and Mortality in Moderate to Severe COVID-19.
In a multicentre Korean cohort of 1,867 hospitalized moderate-to-severe COVID-19 patients, short-term CO exposure increased ARDS risk (OR 1.18 per 0.1 ppm) and 30-day mortality (HR 1.15). Long-term NO2 exposure was also associated with worse outcomes, underscoring the need to incorporate air quality into pandemic risk stratification and public health planning.
Impact: Demonstrates pollutant-specific risks—especially for CO, a commonly under-monitored gas—linking ambient exposures to ARDS and mortality in a large clinical cohort.
Clinical Implications: Air quality metrics, particularly CO, should inform hospital triage and community mitigation strategies during respiratory pandemics. Consider integrating exposure history into prognostic models.
Key Findings
- Short-term CO exposure was associated with higher ARDS incidence (OR 1.18 per 0.1 ppm) and increased 30-day mortality (HR 1.15).
- Long-term NO2 exposure correlated with worse COVID-19 outcomes.
- Associations persisted after accounting for multiple pollutants, highlighting CO as a consistent risk factor.
Methodological Strengths
- Multicentre cohort with individual-level exposure estimates to five pollutants
- Assessment of both short- and long-term exposures with outcome-specific models (ARDS and 30-day mortality)
Limitations
- Observational design with potential residual confounding (e.g., socioeconomic or comorbidity factors)
- Exposure misclassification possible due to modeling assumptions and spatial variability; limited to COVID-19 period and Korean settings
Future Directions: Prospective validation in non-COVID respiratory cohorts; integration of personal exposure sensors; evaluate mitigation (e.g., indoor filtration) effects on clinical outcomes.
BACKGROUND AND OBJECTIVE: Ambient air pollution is known to exacerbate respiratory illnesses. However, its impact on COVID-19 outcomes remains underexplored. We investigated the association between ambient air pollution and outcomes in patients with moderate to severe COVID-19. METHODS: We analysed 1867 hospitalized patients from a multicentre Korean cohort. Individual-level exposure to five air pollutants (SO RESULTS: Short-term CO exposure was associated with increased ARDS incidence (per 0.1 ppm increase OR 1.18) and 30-day mortality (HR 1.15). Long-term NO CONCLUSION: Both short- and long-term exposure to ambient air pollution were associated with worse COVID-19 outcomes, including ARDS and mortality. CO, often overlooked in pollution surveillance, showed the most consistent impact. These findings highlight the importance of air quality in pandemic preparedness and public health policy.
3. Original research: surfactant administration using less invasive surfactant administration (LISA) versus enhanced intubate-surfactant-extubate (ENSURE) in preterm infants.
In an open-label, single-centre RCT (n=118) of preterm infants with RDS, LISA did not reduce invasive mechanical ventilation within 72 hours compared with ENSURE. Secondary outcomes—including duration of respiratory support, BPD, and mortality—were also comparable.
Impact: A head-to-head randomized comparison provides important negative evidence, indicating that standardization and implementation quality may be as crucial as the chosen surfactant technique.
Clinical Implications: Clinicians may consider ENSURE as an acceptable alternative to LISA where expertise or resources vary; focus on protocolized delivery and training may yield greater gains than switching techniques.
Key Findings
- Primary outcome: invasive mechanical ventilation within 72 h was similar (LISA 32.2% vs ENSURE 33.9%; RR 0.95, 95% CI 0.57–1.59; p=0.845).
- Secondary outcomes (duration of respiratory support, BPD, mortality) did not differ between groups.
- Baseline characteristics (gestational age, birth weight, antenatal steroids) were balanced.
Methodological Strengths
- Randomized controlled, head-to-head comparison of two contemporary surfactant strategies
- Predefined primary and secondary outcomes with balanced baseline characteristics
Limitations
- Single-centre, open-label design may limit generalizability and introduce performance bias
- Modest sample size may be underpowered to detect small differences
Future Directions: Multicentre pragmatic trials comparing protocolized delivery and training intensity; evaluation of patient-selection criteria and adjunctive noninvasive support to optimize outcomes.
UNLABELLED: Surfactant replacement therapy improves outcomes in preterm neonates with respiratory distress syndrome (RDS). While the less invasive surfactant administration (LISA) technique offers advantages over intubate-surfactant-extubate (INSURE), the enhanced INSURE (ENSURE) technique has been proposed to address procedural limitations of INSURE. However, direct comparisons between LISA and ENSURE are limited. This study aimed to compare the effectiveness of LISA and ENSURE in reducing the need for mechanical ventilation within 72 h in preterm neonates with RDS. In this open-label, single-center randomized controlled trial conducted at a tertiary-care hospital in North India, 118 preterm neonates (gestational age 26-35 weeks) requiring surfactant therapy were randomized to receive either LISA or ENSURE. The primary outcome was the need for invasive mechanical ventilation within 72 h of surfactant administration. Secondary outcomes included duration of respiratory support, ventilator-free days, intraventricular hemorrhage (IVH), bronchopulmonary dysplasia (BPD), mortality, and other neonatal morbidities. Baseline characteristics, including gestational age (30.6 vs. 31.3 weeks), birth weight (1442 vs. 1537 g), use of antenatal steroids (91.5% vs. 94.9%), were comparable between the two groups. The need for invasive mechanical ventilation within 72 h was similar in the LISA and ENSURE groups (32.2% vs. 33.9%; relative risk 0.95, 95% CI 0.57-1.59; p = 0.845). The duration of respiratory support, incidence of BPD, and mortality was also comparable. CONCLUSION: LISA did not reduce the need for invasive mechanical ventilation within 72 h, duration of respiratory support, or neonatal morbidities and mortality compared with ENSURE. TRIAL REGISTRATION: Clinical Trial Registry of India (CTRI/2023/07/055841). WHAT IS KNOWN: •LISA reduces mechanical ventilation and BPD compared with conventional INSURE by preserving spontaneous breathing and avoiding prolonged positive pressure ventilation. •However, consistent superiority over other surfactant delivery techniques has not been demonstrated, with outcomes influenced by technique, expertise, patient selection, and protocol variability. WHAT IS NEW: •ENSURE showed comparable effectiveness to LISA in reducing invasive mechanical ventilation within 72 h. •These findings underscore that a standardized, protocol-driven surfactant strategy may be as important as the choice of technique.